All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 13: Skin
Toggle Parent Pages
Print this page
Management of eczema
Psoriasis management
Treatment of seborrhoeic dermatitis
Treatment of itching skin (pruritus)
Management of urticaria
Treatment of acne
Treatment of rosacea
Treatment of actinic keratoses
Management of hyperhidrosis
Management of skin conditions
13.2 Emollient and barrier preparations
13.3 Antipruritics
13.4 Topical corticosteroids
13.5 Preparations for eczema and psoriasis
13.6 Acne and rosacea
13.7 Preparations for warts and calluses
13.8 Sunscreens and camouflagers
13.9 Shampoos and other preparations for scalp and hair conditions
13.10 Anti-infective skin preparations
13.11 Skin cleansers, antiseptics, and desloughing agents
13.12 Antiperspirants
13.13 Miscellaneous skin preparations
Contact us about this page
13.6.3 Topical preparations for rosacea
First Line
Second Line
Specialist
Hospital Only
Drugs used for rosacea not listed below:
- Metronidazole gel/cream (see section 13.10.1 Antibacterial preparations)
- Azelaic acid cream 20% (see section 13.6.1 Topical preparations for acne)
Ivermectin
- Cream 10mg/g (£27.43 = 45g)
- Apply once daily over whole facial area avoiding eyes and mucous membranes
Indications
- Treatment of inflammatory lesions of moderate to severe papulopustular Rosacea (moderate to severe)
Notes
- The routine commissioning of ivermectin 10mg/g cream (Soolantra) is accepted in Devon for the treatment of inflammatory lesions of moderate to severe papulopustular rosacea (PPR) (see Commissioning Policy for more details)
Brimonidine (Mirvaso)
The routine commissioning of brimonidine 3mg/g gel (Mirvaso) is not accepted in Devon for the symptomatic treatment of facial erythema of rosacea in adult patients (see Commissioning Policy for more details).
